Of particular interest, 50% of IDH2mut and 83% of IDH1mut AML relapses occurring in IDH triplet treated patients have been IDH wildtype, suggesting effective eradication of the original IDHmut AML and evolution or progression of a separate clone. The gene discussed is IDH2; the disease is acute myeloid leukemia.